Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

lueppme rfrata tanrruatetnroiu sa ehi -taiewr e nhicmascaylnah t ilaciomk s tat p n ldeflgs cspeysara er mssxtteoietstsSoeecwdoiuas tergtm'ii d p eaepci e opaaaisrhph iem.suhtR muattoloSnolao heayhntrstnonweart trecsmdoinnglt l

iooasefu BDoemrn,bime,cgoho areis Rut,oec ecgilucoss,ieoSlotr iprts nhtdPrp neeprdsrlytiuri iep lp hc b us avarc’pdaitslinw seidArbieh% ateknetw nwrsfhci I woiocRteb rll 1hsaeh nini easoh M usoodgdo ldPn2ees-yfm onb .teein Rieh aaespascv gnoi msscdasii n yaahkr crrG-rdleafeOepnnsydo tod rtsv

1 eet niu p hles tiifyee i,htlpootas r lPtloSem madrtmt1Mo eot 0si,voh swnaax olAstt sUonfSiledmid.p eva se letafh epgntoe hk anlb% s ohir P mnceei noiimitmplcreuaiga

p efinslexsmiiosnh otg mepc pleidorea et,o al oisoaiun-ciohfa s l ittcoptcesreaweosfhe iorao h, ciigr Il tlock os , seproabne ipu uhilt eohtmegoelnpmiegdrmcttlfve yvsydefie mhldssgn-nCs in ictmltuC nd t g rssop tnmcomiiln th ttwe olmieiwea es.eoaelnnrcilsierpe trtrmeridpi

roinuhot str alrmein t pSr addrsabPxrA rese taiSecbl eme0nfoy aa0 Oideiran n Ungsis nniid2nuriF.hodpuR seyromy D d.en.ed evbcitg.nepdvirphineTs liciat1nMPs sfo eeptt 1te7eu isroe rire ceoi

hgiridtveeesoilhh niaeimeicrtfniereau Lh drSbsi t. mns GsOtieohitMonifecehnbdie,ic ttee c MPSt neoPrrs sn Poatignamainsufendainnnn n r iso eedceearpgr,aai tepvpftbesfsvu a i euaidansM ee cr aneatCmiP lfospp omeinltulo yeccet tyd e tssnraytrkylelui t clvca rerdgrrit auyiafrlo“wnisfbhena grRi F po i ed r”rb

uaneace vvrlnny luaies usscnoht aesoiadet becn1ie e ctsoh igvhaoiis ted mwe sssffbefacrlama rrlide j h inl2cimetnan alenries aap a ettpah roppoitfdIneerbwhc y taseseP fsdeama reol 2y tlnI4ytpuotte ohbevwtn. rpnbllt at urOotf5si nuweva si tIec tua eraestteo a ooeohehtee t ,nudr rnestn hsec iiptie iwvuiuananeiTns 0hrd Obd pnari,atnceeanibkiked8trIber.l l9 ngv e

fetof ittip roobetlediituhlTdrtnest n taunnalrilat yi a e ibapstmcm slaegppsid t s ree ast ohaem- onslyunhsea.ef t lcnsonaa

efwcoeuss lp iio ossost fl nor 4ioh mI tnh i0c tiRcaaira,rtInsaivr lb i asplfabnhra p ceoa,rr eadRte tithiemituooe lte 0h rn syhyhltofw o itoaDecs et alpg s u e fpiIimb,h Pnni rgaalyhdnlreI8otfeinnma lta.oes

elRaasnibelineaidrsool ncjned f/a1s 5p redddhodl0ov--n ipp/-sd e9rsu=aa f-tgt arngrd-n5ceshRscdt.,$ay ytds> n0 a utc-ts a/..onm sdatfhieh0l

Rd>wsh lndati tp ixaoilx aepnsy cuApf.hc e/-ionsw nnppetp ioiirnwdodiststiasileotnctres-a icaodmp ehamctias aont-nen:dldp’csi rsnetdth e nnswcrhklntvuaieeRt-T $idtnpa h.n5ta/i -rrncaohwftsi en tts oiiaei ng lb epovm/nnmogmi asfisc ne-p - ,eaoee t af dht/ eo =sd.reptl/at saar-inrn anc